Compare CWT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | CDNA |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1997 | 2007 |
| Metric | CWT | CDNA |
|---|---|---|
| Price | $45.35 | $66.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $53.75 | ★ $58.83 |
| AVG Volume (30 Days) | 383.7K | ★ 1.0M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.01 | ★ 2.13 |
| Revenue | ★ $963,695,000.00 | $48,324,000.00 |
| Revenue This Year | $9.24 | $30.36 |
| Revenue Next Year | $6.80 | $6.23 |
| P/E Ratio | $45.59 | ★ $30.04 |
| Revenue Growth | 6.41 | ★ 18.93 |
| 52 Week Low | $41.29 | $13.95 |
| 52 Week High | $53.82 | $65.50 |
| Indicator | CWT | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 78.88 |
| Support Level | $44.63 | $17.26 |
| Resistance Level | $45.58 | N/A |
| Average True Range (ATR) | 0.80 | 2.87 |
| MACD | -0.16 | 0.90 |
| Stochastic Oscillator | 10.88 | 99.39 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.